Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Blood Cells, Molecules & Diseases
|
November 25, 2025
Oxidantscan: A novel biomarker to assess red blood cell susceptibility to oxidative stress in sickle cell disease
C A Hernández, M J M Traets, W W van Solinge, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 1, 2017
Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state
J W R Sins, M Schimmel, B M Luken, et al.
Blood Reviews
|
May 27, 2019
Sickle cell disease: Clinical presentation and management of a global health challenge
M E Houwing, P J de Pagter, E J van Beers, et al.
Leukemia
|
June 8, 2011
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
A W Rijneveld, B van der Holt, S M G J Daenen, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|
January 8, 2009
Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results
A van der Laan, A Hirsch, R Nijveldt, et al.
American Journal of Hematology
|
February 21, 2025
Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease
M J M Traets, J F Bos, S van der Veen, et al.
Leukemia
|
July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
J Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia
|
November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years
J J Cornelissen, J Versluis, J R Passweg, et al.
Leukemia
|
July 22, 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
J J W M Janssen, B Löwenberg, M Manz, et al.
Leukemia
|
August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
G J Ossenkoppele, D A Breems, G Stuessi, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Blood Cells, Molecules & Diseases
|
November 25, 2025
Oxidantscan: A novel biomarker to assess red blood cell susceptibility to oxidative stress in sickle cell disease
C A Hernández, M J M Traets, W W van Solinge, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 1, 2017
Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state
J W R Sins, M Schimmel, B M Luken, et al.
Blood Reviews
|
May 27, 2019
Sickle cell disease: Clinical presentation and management of a global health challenge
M E Houwing, P J de Pagter, E J van Beers, et al.
Leukemia
|
June 8, 2011
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
A W Rijneveld, B van der Holt, S M G J Daenen, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|
January 8, 2009
Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results
A van der Laan, A Hirsch, R Nijveldt, et al.
American Journal of Hematology
|
February 21, 2025
Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease
M J M Traets, J F Bos, S van der Veen, et al.
Leukemia
|
July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
J Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia
|
November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years
J J Cornelissen, J Versluis, J R Passweg, et al.
Leukemia
|
July 22, 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
J J W M Janssen, B Löwenberg, M Manz, et al.
Leukemia
|
August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
G J Ossenkoppele, D A Breems, G Stuessi, et al.
Page
of 5